

Commentary

Open Access

APOAV (T-1131>C) variant has no effect on mother's height in a large population study

Jaroslav A Hubacek*^{1,2}, Zdena Skodova¹, Vera Adamkova¹, Vera Lanska¹, Dagmar Bobkova^{1,2} and Rudolf Poledne^{1,2}

Address: ¹Institute of Clinical and Experimental Medicine, Prague, Czech Republic and ²Centre for Experimental Cardiovascular Research, Prague, Czech Republic

Email: Jaroslav A Hubacek* - jahb@medicon.cz; Zdena Skodova - zdsk@medicon.cz; Vera Adamkova - vead@medicon.cz; Vera Lanska - vela@medicon.cz; Dagmar Bobkova - dabq@medicon.cz; Rudolf Poledne - rupo@medicon.cz

* Corresponding author

Published: 24 May 2004

Received: 02 April 2004

Lipids in Health and Disease 2004, **3**:10

Accepted: 24 May 2004

This article is available from: <http://www.lipidworld.com/content/3/1/10>

© 2004 Hubacek et al; licensee BioMed Central Ltd. This is an Open Access article: verbatim copying and redistribution of this article are permitted in all media for any purpose, provided this notice is preserved along with the article's original URL.

Abstract

The important role of APOAV gene T-1131>C variant in determination of plasma triglyceride levels has been proved on many population studies. Recently, associations between C-1131 allele and higher mother's height as well as with longer fetal birth length were suggested.

In 1,305 females, aged between 28 and 67 years and having at least one child, we have analyzed a putative association between T-1131>C APOAV variant (analyzed by PCR and restriction analysis) and body height.

Mother's body height did not differ between T/T homozygotes (N = 1093, 162.5 ± 6.5 cm) and C allele carriers (N = 212, 162.1 ± 6.4 cm). Thus we have failed to confirm, that mothers with APOAV C-1131 allele are higher than T/T-1131 homozygotes.

Introduction

We read with interest the study by Ward *et al.* [1] on the association between the T-1131>C APOAV variant and plasma levels of triglycerides in pregnancy. In agreement with some previously published population's studies with different design [2-8], they described an association between higher levels of plasma triglyceride and the presence of C-1131 allele also in a group of healthy pregnant women. Additionally, they have found an interesting association between allele C-1131 and higher mother's height and as well as with fetal birth length.

The T-1131>C variant has been intensively studied over the last couple of years. The C allele is undoubtedly associated not just with higher plasma TG levels [2-7], but also with higher VLDL-TG levels [9] what could influence fetal

growth [10,11] and theoretically also final height of the body in adulthood, as suggested by Ward *et al.* [1].

Discussion

Using a previously described method [5,12], we analyzed the T-1131>C variant in a total of 1,367 unrelated Caucasians females aged 48.8 ± 10.6 years in 2000/2001 recruited as a representative 1% population sample [*Multinational monitoring of trends and determinants in cardiovascular diseases: MONICA Project, Manual of operations WHO/MNC 82.2, Nov 1983*]. Written informed consent was obtained before the blood samples were taken and measurements being performed. 62 females have no children. In 1,305 females, having at least one child, we have analyzed a putative association between APOAV T-1131>C variant and body height by ANOVA. The size of

Table 1: APOAV T-1131>C variant and height in women

APOAV genotype	T-1131T	+ C-1131
N	1093	212
Height (cm)	162.5 ± 6.5	162.1 ± 6.4

Data are presented as means ± s. d. No significant association was found.

the analyzed population minimized the chances of false negative or false positive results.

As mentioned before, standard association between elevated levels of plasma triglycerides and the presence of the C-1131 allele was found [5,6].

In contrast to Ward *et al.* [1], we found no association between the T-1131>C variant in the APOAV gene and mother's body height, see Table 1. Thus the association described by Ward *et al.* [1] need not be generally valid.

Plasma triglycerides represent the most important source of fatty acids utilized by fetus through pregnancy. About 50% of these fatty acids are derived from maternal circulation [13]. It has been found that maternal VLDL-TG concentrations are positively correlated with birth weight [10,11]. In respect of these findings the same effect of VLDL-TG concentrations on birth length could be supposed. However results reveal that birth length seemed to be affected by many maternal factors [10] shading expected effect of TG.

Nevertheless, adult body height, which slightly correlate with birth length, although undoubtedly genetically determined, will be in last century strongly influenced by abundant availability of food sources in industrially developed countries and this environmental effect could mask the influence of the genes.

Conclusions

More than 1300 unrelated Caucasian females were included in this study. We conclude that the T-1131>C variant in the APOAV gene has no general effect on mother's body height. Nevertheless, APOAV gene and its variants [3,14] remain to be candidate gene for genetic determination of newborn's length/weight.

References

1. Ward KJ, Shields B, Knight B, Salzman MB, Hattersley AT, Frayling TM: **Genetic variants in Apolipoprotein AV alter triglyceride concentrations in pregnancy.** *Lipids Health Dis* 2003, **2**:9.
2. Pennacchio LA, Olivier M, Hubacek JA, Cohen JC, Cox DR, Fruchart JC, Krauss RM, Rubin EM: **An apolipoprotein influencing triglycerides in humans and mice revealed by comparative sequencing.** *Science* 2001, **294**:169-73.
3. Pennacchio LA, Olivier M, Hubacek JA, Krauss RM, Rubin EM, Cohen JC: **Two independent apolipoprotein AV haplotypes influence human plasma triglyceride levels.** *Hum Mol Genet* 2002, **11**:3031-8.
4. Nabika T, Nasreen S, Kobayashi S, Masuda J: **The genetic effect of the apolipoprotein AV gene on the serum triglyceride level in Japanese.** *Atherosclerosis* 2002, **165**:201-4.
5. Hubacek JA, Skodova Z, Adamkova V, Lanska V, Poledne R: **The influence of APOAV polymorphisms (T-1131>C and S19>W) on plasma triglyceride levels and risk of myocardial infarction.** *Clin Genet* 2004, **65**:126-30.
6. Hubacek JA, Skodova Z, Adamkova V, Vrablik M, Horinek A, Lanska V, Ceska R, Poledne R: **APOAV polymorphisms (T-1131/C and Ser19/Trp) influence plasma triglyceride levels and risk of myocardial infarction.** *Exp Clin Cardiol* 2004 in press.
7. Talmud PJ, Hawe E, Martin S, Olivier M, Miller GJ, Rubin EM, Pennacchio LA, Humphries SE: **Relative contribution of variation within the APOC3/A4/A5 gene cluster in determining plasma triglycerides.** *Hum Mol Genet* 2002, **11**:3039-46.
8. Seda O, Sedova L: **New apolipoprotein A-V: comparative genomics meets metabolism.** *Physiol Res* 2003, **52**:141-6.
9. Talmud PJ, Martin S, Taskinen MR, Frick MH, Nieminen MS, Kesaniemi YA, Pasternack A, Humphries SE, Syvanne M: **APOA5 gene variants, lipoprotein particle distribution and progression of coronary heart disease: results from the LOCAT study.** *J Lipid Res* 2004, **45**:750-756.
10. Coleman RA: **Placental metabolism and transport of lipid.** *Fed Proc* 1986, **45**:2519-23.
11. Knopp RH, Bergelin RO, Wahl PW, Walden CE: **Relationships of infant birth size to maternal lipoproteins, apoproteins, fuels, hormones, clinical chemistries, and body weight at 36 weeks gestation.** *Diabetes* 1985, **Suppl 2**:71-7.
12. Horinek A, Vrablik M, Ceska R, Adamkova V, Poledne R, Hubacek JA: **T-1131->C polymorphism within the apolipoprotein AV gene in hypertriglyceridemic individuals.** *Atherosclerosis* 2003, **167**:369-70.
13. Nolan CJ, Riley SF, Sheedy MT, Walstab JE, Beischer NA: **Maternal serum triglyceride, glucose tolerance, and neonatal birth weight ratio in pregnancy.** *Diabetes Care* 1995, **18**:1550-6.
14. Hubacek JA, Adamková V, Ceska R, Poledne R, Horinek A, Vrablik M: **New variants in the apolipoprotein AV gene in individuals with extreme triglyceride levels.** *Physiol Res* 2004, **53**:225-8.

Publish with **BioMed Central** and every scientist can read your work free of charge

"BioMed Central will be the most significant development for disseminating the results of biomedical research in our lifetime."

Sir Paul Nurse, Cancer Research UK

Your research papers will be:

- available free of charge to the entire biomedical community
- peer reviewed and published immediately upon acceptance
- cited in PubMed and archived on PubMed Central
- yours — you keep the copyright

Submit your manuscript here:
http://www.biomedcentral.com/info/publishing_adv.asp

